drugset / Trial / NCT00710021

Vitamin D3 in Systemic Lupus Erythematosus

NCT00710021

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.

Timeline

Start
2008-11
Primary completion
2011-07
Completion
2011-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 2000 iu Oral
Subject Cholecalciferol Other / unclassified 4000 iu Oral